Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing
Journal of Allergy and Clinical Immunology · 2024
DOI: 10.1016/j.jaci.2023.11.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Anne Rensing-Ehl und 44 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University o…. Hauptthemen laut MEDLINE: Autoimmune Lymphoproliferative Syndrome, fas Receptor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Wilhelm Sander Foundation, German Federal Ministry of Health.
Abstract (Originalsprache)
BACKGROUND: Elevated TCRαβ+CD4-CD8- double-negative T cells (DNT) and serum biomarkers help identify FAS mutant patients with autoimmune lymphoproliferative syndrome (ALPS). However, in some patients with clinical features and biomarkers consistent with ALPS, germline or somatic FAS mutations cannot be identified on standard exon sequencing (ALPS-undetermined: ALPS-U). OBJECTIVE: We sought to explore whether complex genetic alterations in the FAS gene escaping standard sequencing or mutations in other FAS pathway-related genes could explain these cases. METHODS: Genetic analysis included whole FAS gene sequencing, copy number variation analysis, and sequencing of FAS cDNA and other FAS pathway-related genes. It was guided by FAS expression analysis on CD57+DNT, which can predict somatic loss of heterozygosity (sLOH). RESULTS: Nine of 16 patients with ALPS-U lacked FAS expression on CD57+DNT predicting heterozygous "loss-of-expression" FAS mutations plus acquired somatic second hits in the FAS gene, enriched in DNT. Indeed, 7 of 9 analyzed patients carried deep intronic mutations or large deletions in the FAS gene combined with sLOH detectable in DNT; 1 patient showed a FAS exon duplication. Three patients had reduced FAS expression, and 2 of them harbored mutations in the FAS promoter, which reduced FAS expression in reporter assays. Three of the 4 ALPS-U patients with normal FAS expression carried heterozygous FADD mutations with sLOH. CONCLUSION: A combination of serum biomarkers and DNT phenotyping is an accurate means to identify patients with ALPS who are missed by routine exome sequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: anne.rensing-ehl@un…
- Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Wuerttemberg - Hessen, Ulm, Germany.
- Clinic for Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria; Syndena GmbH, Connect to cure, Innsbruck, Austria.
- Clinic for Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria.
- Clinic for Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria; Tyrolean Cancer Research Institute, Innsbruck, Austria.
Förderung
- Wilhelm Sander Foundation
- German Federal Ministry of Health
Zitieren
APA
Rensing-Ehl, A., Lorenz, M. R., Führer, M., Willenbacher, W., Willenbacher, E., Sopper, S., Abinun, M., Maccari, M. E., König, C., Haegele, P., Fuchs, S., Castro, C., Kury, P., Pelle, O., Klemann, C., Heeg, M., Thalhammer, J., Wegehaupt, O., Fischer, M., …, & ALPS Study Group (2024). Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.11.006
Vancouver
Rensing-Ehl A, Lorenz MR, Führer M, Willenbacher W, Willenbacher E, Sopper S, et al. Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2023.11.006
BibTeX
@article{RensingEhl2024,
author = {Rensing-Ehl, Anne and Lorenz, Myriam Ricarda and Führer, Marita and Willenbacher, Wolfgang and Willenbacher, Ella and Sopper, Sieghart and Abinun, Mario and Maccari, Maria Elena and König, Christoph and Haegele, Pauline and Fuchs, Sebastian and Castro, Carla and Kury, Patrick and Pelle, Olivier and Klemann, Christian and Heeg, Maximilian and Thalhammer, Julian and Wegehaupt, Oliver and Fischer, Marco and Goldacker, Sigune and Schulte, Björn and Biskup, Saskia and Chatelain, Philippe and Schuster, Volker and Warnatz, Klaus and Grimbacher, Bodo and Meinhardt, Andrea and Holzinger, Dirk and Oommen, Prasad Thomas and Hinze, Tanja and Hebart, Holger and Seeger, Karlheinz and Lehmberg, Kai and Leahy, Timothy Ronan and Claviez, Alexander and Vieth, Simon and Schilling, Freimut H and Fuchs, Ilka and Groß, Miriam and Rieux-Laucat, Frederic and Magerus, Aude and Speckmann, Carsten and Schwarz, Klaus and Ehl, Stephan and ALPS Study Group, ALPS Study Group},
title = {Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
doi = {10.1016/j.jaci.2023.11.006}
}
EUVIMED